Patient Reported Outcomes Following Stereotactic Ablative Radiotherapy or Surgery for Stage IA Non-small-cell Lung Cancer: Results from the ROSEL Multicenter Randomized Trial

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2015 Oct 24

PMID 26492839

Citations 38

Authors

Alexander V Louie

Erik van Werkhoven

Hanbo Chen

Egbert F Smit

Marinus A Paul

Joachim Widder

Harry J M Groen

Ben E E M van den Borne

Katrien De Jaeger

Ben J Slotman

Suresh Senan

Affiliations

Soon will be listed here.

Abstract

We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy or SBRT) versus surgical resection for medically operable stage IA non-small cell lung cancer. ROSEL closed prematurely after accruing and randomizing 22 patients. This exploratory analysis found the global health related quality of life and indirect costs to be significantly favorable and cheaper, with SABR.

Citing Articles

New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights.

Buono M, Russo G, Nardone V, Della Corte C, Natale G, Rubini D J Liq Biopsy. 2025; 5:100153.

PMID: 40027942 PMC: 11863942. DOI: 10.1016/j.jlb.2024.100153.

Surgery Versus Stereotactic Radiotherapy in Patients over 75 Years Treated for Stage IA-IIA NSCLC.

Oliver G, Boucekine M, Couderc A, Fourdrain A, Zaccariotto A, Pougnet I Cancers (Basel). 2025; 17(4).

PMID: 40002271 PMC: 11853726. DOI: 10.3390/cancers17040677.

Dosimetric Analysis of Proximal Bronchial Tree Subsegments to Assess The Risk of Severe Toxicity After Stereotactic Body Radiation Therapy of Ultra-central Lung Tumors.

Ahmadsei M, Jegarajah V, Dal Bello R, Christ S, Mayinger M, Sabrina Stark L Clin Transl Radiat Oncol. 2023; 45:100707.

PMID: 38125648 PMC: 10731610. DOI: 10.1016/j.ctro.2023.100707.

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.

Volpe S, Zaffaroni M, Piperno G, Vincini M, Zerella M, Mastroleo F BMC Cancer. 2023; 23(1):1236.

PMID: 38102575 PMC: 10722797. DOI: 10.1186/s12885-023-11701-9.

Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT.

Ahmadsei M, Thaler K, Gasser E, Pouymayou B, Dal Bello R, Christ S Clin Transl Radiat Oncol. 2023; 43:100675.

PMID: 37744054 PMC: 10511337. DOI: 10.1016/j.ctro.2023.100675.